Background: This study assessed the frequency of short-term oral corticosteroid use in adults with diabetes, examined the incidence of fractures, venous thromboembolism (VTE), and hospitalization for sepsis after corticosteroid use, and evaluated whether preventative medications mitigated adverse events. Methods: A longitudinal study was conducted of 1 548 945 adults (aged 18-64 years) who received healthcare coverage through a large national health insurer. Incidence rate ratios (IRR) were calculated using conditional Poisson regression. Results: Short-term oral corticosteroids were used by 23.9%, 20.8%, and 20.9% of adults with type 2 diabetes, type 1 diabetes, and no diabetes, respectively, during the 3-year period (P < 0.001). Baseline risks of fracture, VTE, and sepsis were greater for individuals with than without diabetes (P < 0.001). The combined effect of having diabetes and using corticosteroids was greater than the sum of the individual effects (synergy indices of 1.17, 1.23, 1.30 for fracture, VTE, and sepsis, respectively). The IRR for VTE in the 5-30 days after corticosteroid use was 3.62 (95% confidence interval [CI] 2.41-5.45). Fractures increased in the 5-30 days after corticosteroid use (IRR 2.06; 95% CI 1.52, 2.80), but concomitant use of ergocalciferol mitigated this risk (IRR 1.13; 95% CI 0.12, 11.07). The risk of hospitalization for sepsis was elevated with corticosteroid use (IRR 3.79; 95% CI 2.05, 7.01), but was mitigated by the concomitant use of statins. Conclusions: Short-term oral corticosteroid use is common in adults with diabetes and is associated with an elevated, but low, risk of adverse events. The findings suggest that preventative medications may mitigate risk.
Introduction
Oral corticosteroids decrease insulin secretion, promote gluconeogenesis and glycogenolysis, and diminish hepatic and skeletal muscle insulin sensitivity; 1 therefore, their use in patients with diabetes mellitus requires close surveillance. Guidelines for diabetes management include recommendations for careful monitoring of blood glucose when beginning the use of oral corticosteroids and for caution when insulin dosing corrections are made to compensate for the anticipated hyperglycemia. [2] [3] [4] This is notable because corticosteroid use is common; [5] [6] [7] for example, approximately one-fifth of the US working-age population uses short-term corticosteroids. 8 Aside from hyperglycemia, the pleiotropic side effects of long-term oral corticosteroid use are well recognized. 9 The use of oral corticosteroids for short periods has been generally considered safe, but recently has been implicated in the risk of adverse events (AEs), albeit at rather low frequencies. 8 Because AEs may occur infrequently, it is not always possible to evaluate such risks within the context of a randomized controlled trial due to low statistical power. Trials also impose a challenge for the evaluation of patient safety due to the dissimilarity of trial participants to the wider population of patients who may be taking the medications. Moreover, many trials do not assess all risks; for example, investigators found that venous thromboembolism (VTE) was not reported in 89% of randomized controlled trials. 10 Therefore, the evaluation of patient safety is often undertaken during the post-trial period using data from a larger population of users.
We were particularly interested in the safety of medications in the young and middle-aged adult populations with diabetes because of the lack of studies in adults of working age. We obtained data from a large, national sample of American adults who received private healthcare coverage. The purpose of the present study was twofold: (i) to assess the frequency of short-term oral corticosteroid use in adults with diabetes; and (ii) to examine the incidence of fractures, VTE, and hospitalization for sepsis by corticosteroid use. In addition, we assessed whether there were potential mitigating factors that may affect this risk.
Methods
A longitudinal study was conducted using de-identified data collected from 1 January 2012 through 31 December 2014 from adults (18-64 years of age) who received healthcare coverage through a large national health insurer (obtained through OptumInsight, Eden Prairie, MN, USA). The study was reviewed by the University of Michigan Institutional Review Board for oversight regarding human subjects, designated as exempt from further review, and given a waiver for informed consent. There were 1 548 945 adults in the database, and the study methods have been described in detail elsewhere. 8 Briefly, adults with 3 years of continuous enrollment with the national health insurer were included to assess corticosteroid use and the incidence of fracture, VTE, and hospitalization for sepsis. Because we were studying incident events, those individuals who experienced fractures, VTE or sepsis in 2011 were excluded from the study. Over the 3-year period of the study , the first occurrence for each outcome was extracted so as to not capture follow-up visits for the same event.
Oral corticosteroid use of short duration (<30 days) was extracted from pharmacy files, indicating the type of prescription(s) and the date(s) when filled. Patients who were prescribed oral corticosteroids for ≥30 days cumulatively over the study period were excluded, as were those who received any oral corticosteroids during the year prior to the start of the study (in 2011). The oral corticosteroids identified were betamethasone, dexamethasone, methylprednisolone, triamcinolone, prednisone, prednisolone, hydrocortisone, and cortisone. We focused on oral corticosteroids that were swallowed (e.g. tablets, capsules, elixirs) and excluded all other forms of corticosteroids, including aerosols, creams, drops, suspended drops, lotion, spray, and vials.
Patients with type 1 diabetes mellitus (T1DM) were defined as individuals who had at least two International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM; https://www.cdc.gov/ nchs/icd/icd9cm.htm, accessed 12 May 2017) codes indicating T1DM on different dates, with the use of insulin (Table 1) . Patients with type 2 diabetes mellitus (T2DM) were identified as individuals with records of at least two ICD-9-CM codes indicating T2DM on different dates, regardless of type of antidiabetic medication used (Table 1) . Outcomes (fracture, VTE, sepsis) were also ascertained through ICD-9-CM codes. For sepsis, hospital admissions were used in which the principal diagnosis was sepsis. Fractures of the torso and limbs were included from injury codes (Table 1) .
There were no missing values for age or gender. There were complete data regarding diagnoses and medication prescriptions that were filled by the participants within this health insurance plan during the time period of the study.
Statistical analysis
There were several phases to the statistical analyses. In the first phase, we examined the frequency (%) of corticosteroid use (with 95% exact confidence intervals [CI] ), stratified by type of diabetes, gender, and age category. To assess differences in the frequency of use by subgroup, Pearson's Chi-squared tests were used.
In the second phase of the analyses, we assessed the frequency of AEs (fractures, VTE, and hospitalization for sepsis). Both cumulative incidence (%) and rates (events/1000 person-years) were calculated with 95% CIs, stratified by type of diabetes. Incidence rate ratios (IRR) were also calculated, comparing the event rate in corticosteroid users with that in non-steroid users, with stratification by type of diabetes. The interaction between steroid use and diabetes on AEs was determined by using the synergy index on an additive scale.
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A synergy index >1.0 indicates a positive interaction; that is, the combined effect of having diabetes and using corticosteroids would be greater than the sum of the individual effects of these two factors. In addition, we examined the association between corticosteroid use and AEs when stratified by the type of antidiabetic medication used (i.e. ever used during the study period); odds ratios (ORs) were generated from a logit model with adjustment for age, gender, and race. Heterogeneity by type of antidiabetic medication was evaluated using Cochran's Q test and the I 2 statistic, which measures the percentage of variation in the ORs (across the various antidiabetic medications) that is due to heterogeneity rather than random error.
In the third phase of the analyses, the association between corticosteroid use and AEs was evaluated. Using a self-controlled case series design, the incidence of AEs after corticosteroid use was calculated and compared with the incidence of AEs during the time period when the corticosteroid was not used. That is, the incidence of events was compared in different time windows within the same person. We assessed risk of AEs in the 5-30, 31-90, and 91-180 days after the corticosteroid prescription was filled. The reference (comparator) period was 5-180 days prior to when the corticosteroid prescription was filled. Conditional (fixed) Poisson regression was used for the analyses, offset by the natural logarithm of the time under observation. Incidence rate ratios were generated with 95% CI comparing the risk of AEs when using versus not using corticosteroids. Because this was a within-person comparison, gender, race, genetic profile, history of past medical conditions, and past health-related behaviors remained the same. Other non-steroidal medications that were significantly associated with the outcomes were included as time-varying covariates.
In a secondary analysis of patients with diabetes, the self-controlled case series design was extended to examine whether the use of preventative medications at the same time as the corticosteroids affected the results. Specifically, concomitant use (prescription filled 0-30 days prior to the corticosteroid prescription) of vitamin D and statin was determined. Use of corticosteroids with vitamin D was of interest for the assessment of fractures. Use of corticosteroids with statin was of interest for VTE and sepsis. Statistical methods were similar to those described above (i.e. fixed Poisson regression with an offset). In addition, we used a cohort design to further investigate the association between concomitant medications and AEs (comparing users with non-users) in which logistic regression was used. Alpha was set at 0.05, two-tailed. All analyses were conducted in Stata/MP 14.2 (StataCorp, College Station, TX, USA).
Results
In the present study, 8.1% (126 091/1 548 945) of adults had diabetes mellitus. Of those with diabetes, 87.4% (110 141/126 091) had T2DM and 12.6% (15 950/ 126 091) had T1DM. The mean (AE SD) age of those with T2DM, with T1DM, and those without diabetes was 53.3 AE 8.2), 49.5 AE 11.4, and 43.6 AE 12.1 years, respectively. Men were more likely to have diabetes than women (60% males with T1DM, 59% males with T2DM, 54% males without diabetes; P < 0.001). Within this database, 21.1% (327 452/1 548 945) used corticosteroids for <30 days. Individuals with T2DM were more likely to use corticosteroids than those with T1DM and those without diabetes (P < 0.001 for both). The frequency of corticosteroid use is given in Table 2 , by diabetes type, gender, and age categories. Women with T2DM were frequent users of short-duration corticosteroids (28.4% during the 3-year study period). Across both gender and age categories, individuals with T2DM were more frequent users of corticosteroids than either those with T1DM or those without diabetes. The mean (AE SD) duration of corticosteroid therapy in patients with diabetes was 6.7 AE 3.0 days, whereas the median (interquartile range) duration was 6 days (5-7 days).
Rates of fracture, VTE, and hospitalization for sepsis are given in Table 3 . Adults with T1DM had greater rates of AEs than those with T2DM and those without diabetes (P < 0.001 for both). In adults with T1DM who used corticosteroids, 12.5% experienced a fracture, 4.6% experienced VTE, and 4.4% were hospitalized for sepsis during the study period. This compares with 7.2%, 2.6%, and 1.4%, respectively, for adults with T2DM. The IRRs indicate that the risks of AEs were significantly elevated in patients with diabetes (both T1DM and T2DM) and in corticosteroid users (vs non-users without diabetes), although the strength of the association was greater in those with T1DM (Table 3) . For example, the risk of VTE was sevenfold greater in patients with T1DM who used corticosteroids than in non-users without diabetes. All outcomes exhibited positive interactions (synergy indices of 1.17, 1.23, and 1.30 for fracture, VTE, and sepsis, respectively). Therefore, the combined effect of having diabetes and using corticosteroids was greater than the sum of the individual effects.
When stratified by the type of antidiabetic medication used, the association between corticosteroid use and AEs remained (Fig. 1) . The results indicate that there was no significant heterogeneity in the ORs, regardless of the outcome (P = 0.360 for fracture, P = 0.962 for VTE, P = 0.465 for sepsis). The I 2 (measure of inconsistency) for fracture, VTE, and sepsis was 9.0%, 0%, and 0%, respectively. Therefore, the odds for developing the three AEs were significantly elevated for corticosteroid users (vs non-users), regardless of the type of antidiabetic medication used during the period of the study.
The results from the self-controlled case series are listed in Table 4 . The risk of AEs was greatest during the 5-to 30-day period after the corticosteroid prescription was filled for those with diabetes (IRR 2.06 for fracture, IRR 3.62 for VTE, and IRR 3.79 for sepsis). For all three outcomes, the IRRs tended to decrease over time. The results for those without diabetes are given in Table 5 , indicating that the relative risk of AEs was similar for those with and without diabetes, although the underlying baseline risk (cumulative incidence) was was greater in those with diabetes (Table 3) .
We also evaluated the addition of potential preventative medications on the relationship between corticosteroids (Table 4) indicate that adults with diabetes had a twofold increase in the incidence of fracture in the 5-to 30-day period after the corticosteroid prescription was filled. However, those patients with diabetes who were taking vitamin D with the corticosteroids did not experience an increased risk (IRR 1.13). Those taking corticosteroids without vitamin D had an elevated risk (IRR 2.09).
We also examined the risk of fracture using the conventional cohort design, comparing individuals with diabetes who used with those who did not use the medications (Table 6 ). The risk of fracture was lowest (4.4%) in adults with diabetes who used vitamin D but no corticosteroids. The highest risk of fracture was 8.1% in adults with diabetes who used corticosteroids but no vitamin D. The odds of fracture were 1.37-fold greater in those using corticosteroids without vitamin D than in those who did not use either of these medications. In this database, 61.4% (77 419/126 091) of individuals with diabetes ever used statins during the 3-year study period. The risk of VTE was elevated (IRR 3.62) during the 5-to 30-day period after the corticosteroid was taken (Table 4) , but this risk declined over time.
Results from the self-controlled case series indicated that the addition of statins did not appreciably affect the rate ratios for VTE; the risk remained elevated regardless of statin use. For sepsis, however, the use of corticosteroids without statin yielded a significant IRR of 4.91 (Table 4) . When patients with diabetes used statins concomitantly with the corticosteroids, there was no significant elevation in sepsis risk.
We also evaluated corticosteroids with statins using the conventional cohort approach ( Table 6 ). The greatest risk of an AE occurred in adults with diabetes who used corticosteroids without statins (3.3% for VTE, 2.1% for sepsis). The odds of VTE were 51% greater in those using corticosteroids without statins compared with those using neither (Table 6 ). However, the odds of VTE were not elevated when the corticosteroids were used with statins (OR 1.04). In addition, the odds of hospitalization for sepsis were lower when statins were used concomitantly with corticosteroids (OR 0.77) than when using neither; the (multiplicative) interaction term between corticosteroids and statins was significant (P = 0.013). The use of statins modified the association between corticosteroids and hospitalization for sepsis.
Discussion
In the present study, adults with diabetes were found to be frequent users of short-term oral corticosteroids. Use was particularly common in T2DM, affecting one in four patients, whereas use occurred in one of five individuals with T1DM, and in one of five people without diabetes. Short-term use was higher in middle-aged adults compared with younger adults, and was frequent in women with T2DM, affecting 28.4% during the 3-year study period.
The higher rates of fracture, VTE, and hospitalization for sepsis in patients with diabetes confirm results from previous investigations. [12] [13] [14] However, the present study extends the current literature with the finding of synergy between diabetes and corticosteroid use. The risks of AEs were more elevated with these two factors together than for each one separately. This suggests that efforts to prevent adverse outcomes with oral corticosteroids may be better targeted to individuals with diabetes than those without. Patients with T1DM may particularly benefit because of their higher baseline risk. For individuals with T2DM, the elevation in risk of AEs after corticosteroid use remained, regardless of the type of antidiabetic medications used.
Although there was an elevated risk of AEs after corticosteroid use, the findings suggest that certain concomitant medications could possibly mitigate risk. When individuals with diabetes used both corticosteroids and ergocalciferol (50 000 IU weekly), there was no elevated risk of fracture, but when corticosteroids were used without ergocalciferol there was a twofold increased risk of fracture. Data from the National Health and Nutrition Examination Survey, a nationally representative sample, demonstrated an association between corticosteroid use and 25-hydroxyvitamin D (25(OH)D) deficiency. 15 In a meta-analysis of 25 studies, adults receiving corticosteroid therapy were found to have low serum 25(OH)D levels that were insufficient to prevent osteoporosis. 16 . The US Preventive Services Task Force reviewed the data and found inconclusive evidence regarding vitamin D supplementation on the risk of fractures in older adults, but there were no trials in high-risk populations of middle-aged adults. 17 The present study found several high-risk populations in adults aged 18-65 years; these include corticosteroid users and individuals with diabetes. The results, suggesting that the use of 50 000 IU ergocalciferol may mitigate the effects of corticosteroid use in middle-aged adults with diabetes, should be confirmed in randomized controlled trials. Ergocalciferol is associated with minimal risk and it is significant that 42% of Americans (in general) are vitamin D deficient, as are 82% of African Americans and 69% of Hispanics in the US. 18 We also found that the use of statins affected the association between corticosteroids and hospitalization Sepsis was adjusted for antibiotics, 5-hydroxytryptamine 5-HT 3 receptor antagonists, antidepressants, anti-inflammatory agents, antimuscarinics, opiate agonists, and phenothiazine. Venous thromboembolism was adjusted for antibiotics, androgens, anxiolytics, anti-inflammatory agents, azoles, calcium channel blockers, coumarin, diuretics, opiate agonists, and platelet aggregation inhibitors. Fractures were adjusted for anti-inflammatory agents, cyclo-oxygenase 2 inhibitors, and opiate agonists. CI, confidence interval; IRR, incidence rate ratio. Sepsis was adjusted for antibiotics, 5-hydroxytryptamine 5-HT 3 receptor antagonists, antidepressants, anti-inflammatory agents, antimuscarinics, opiate agonists, and phenothiazine. Venous thromboembolism was adjusted for antibiotics, androgens, anxiolytics, anti-inflammatory agents, azoles, calcium channel blockers, coumarin, diuretics, opiate agonists, and platelet aggregation inhibitors. Fractures were adjusted for anti-inflammatory agents, cyclo-oxygenase 2 inhibitors, and opiate agonists. CI, confidence interval; IRR, incidence rate ratio. for sepsis. Both the self-controlled case series (withinperson approach) and the cohort study (between-person approach) suggested that statins modified this association. Previous studies have shown that statins decrease the rate of severe sepsis and intensive care admissions. [19] [20] [21] Moreover, rates of hospitalization for infection have been found to be significantly elevated in patients who use corticosteroids, 22 and extended corticosteroid use has long been associated with immunosuppression and higher infection rates. 1 Because statin use is recommended for many adults with diabetes (based on the estimated 10-year cardiovascular disease risk), 23, 24 randomized trials may be necessary to more clearly delineate potential benefits of adding statins to short-term corticosteroids for those patients with diabetes who are not currently receiving statins.
There are limitations of the present study. Information was not available on levels of C-peptide and glutamic acid decarboxylase autoantibodies for all individuals with diabetes. The use of ICD-9-CM diagnosis codes and medication use to discern diabetes may have resulted in some misclassification. However, validation studies indicate that the use of 250xx diagnosis codes for diabetes (captured over a 1-year period) had a sensitivity of 97%, specificity of 97%, and positive predictive value of 98%. 25 In a study to distinguish diabetes type, the use of two or more T1DM codes yielded a sensitivity of 90% 26 and a positive predictive value of 91.3% for the identification of T1DM. 27 A prescription for insulin had a sensitivity of 95% for T1DM. 26 Another limitation of the present study is that we could not rule out confounding by indication; that is, the illness that prompted the patient's visit to the physician could be a contributing factor of the AE. However, infection, thromboembolism, and decreases in bone density are all listed as possible AEs on Food and Drug Administration package inserts of corticosteroids, indicating prior evidence of association. 28, 29 With the use of short-term oral corticosteroids, we found that the absolute risk of such AEs was modest; for example, of 1000 patients with T1DM who used corticosteroids, 43 experienced a fracture over a 1-year period. This compared with 32 patients experiencing a fracture who did not use corticosteroids.
The use of a self-controlled case series is a particularly strong design for addressing other confounding factors. The present findings cannot be explained by dissimilarities in genetic profiles for different individuals because the comparison was within the same person. Similarly, other personal characteristics, such as past history of VTE, history of cancer, former smoking habits, and past personal characteristics, were controlled. Because the comparator is the person him/herself, these factors (and the interactions among such factors) are held constant.
We conclude that the use of oral corticosteroids for short durations is common in patients with diabetes and is associated with an elevated (but modest) risk of fracture, VTE, and hospitalization for sepsis. The addition of ergocalciferol to prevent fractures and the addition of statins to prevent hospitalization for sepsis should be investigated in randomized trials, particularly in patients with diabetes who use corticosteroids.
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